Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma

Journal of Clinical Oncology

Volumn 30, Issue 28, 2012, Pages 3525-3532

  Asgharzadeh, Shahab ^a,b   Salo, Jill A ^a   Ji, Lingyun ^b   Oberthuer, André ^f   Fischer, Matthias ^f   Berthold, Frank ^f   Hadjidaniel, Michael ^a   Liu, CathyWei Yao ^a   Metelitsa, Leonid S ^g   Pique Regi, Roger ^h   Wakamatsu, Peter ^a   Villablanca, Judith G ^a,b   Kreissman, Susan G ⁱ   Matthay, Katherine K ^c   Shimada, Hiroyuki ^a,b   London, Wendy B ^d,e   Sposto, Richard ^a,b   Seeger, Robert C ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY OF COLOGNE   (Germany)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; CD163 ANTIGEN; CD33 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6 RECEPTOR;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INFILTRATION; CHILD; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MYCN NONAMPLIFIED NEUROBLASTOMA; NEUROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CALCIUM-BINDING PROTEINS; CHILD, PRESCHOOL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; GENE AMPLIFICATION; HUMANS; INFANT; INFLAMMATION; MACROPHAGES; NEOPLASM METASTASIS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; RECEPTOR, TRKB; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN-6; TRANS-ACTIVATORS;

EID: 84867052186     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.9169     Document Type: Article

References (54)

1. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 144:646-674, 2011
2. Steidl C, Lee T, Shah SP, et al: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362:875-885, 2010
3. Ueno T, Toi M, Saji H, et al: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6:3282-3289, 2000 (Pubitemid 30637758)
4. DeNardo DG, Brennan DJ, Rexhepaj E, et al: Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1:54-67, 2011
5. Bronkhorst IH, Ly LV, Jordanova ES, et al: Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci 52:643-650, 2011
6. Kurahara H, Shinchi H, Mataki Y, et al: Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 167:e211-e219, 2011
7. Cohn SL, Pearson AD, London WB, et al: The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol 27:289-297, 2009
8. Deyell RJ, Attiyeh EF: Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma. Cancer Genet 204:113-121, 2011
9. Schmidt ML, Lukens JN, Seeger RC, et al: Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol 18:1260-1268, 2000 (Pubitemid 30159844)
10. Matthay KK, Reynolds CP, Seeger RC, et al: Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group study. J Clin Oncol 27:1007-1013, 2009
11. Simon T, Hero B, Faldum A, et al: Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer 11:21, 2011
12. Berthold F, Boos J, Burdach S, et al: Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: A randomised controlled trial. Lancet Oncol 6:649-658, 2005 (Pubitemid 41222755)
13. Cheung NK, Kushner BH, Kramer K: Monoclonal antibody-based therapy of neuroblastoma. Hematol Oncol Clin North Am 15:853-866, 2001 (Pubitemid 34026974)
14. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid: Children's Cancer Group. N Engl J Med 341:1165-1173, 1999 (Pubitemid 29480654)
15. George RE, Li S, Medeiros-Nancarrow C, et al: High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: Long-term survival update. J Clin Oncol 24:2891-2896, 2006 (Pubitemid 46630591)
16. Yu AL, Gilman AL, Ozkaynak MF, et al: Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324-1334, 2010
17. Schmidt ML, Lal A, Seeger RC, et al: Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: A Children's Cancer Group Study. J Clin Oncol 23:6474-6480, 2005 (Pubitemid 46190238)
18. Baker DL, Schmidt ML, Cohn SL, et al: Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 363:1313-1323, 2010
19. George RE, London WB, Cohn SL, et al: Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 23:6466-6473, 2005 (Pubitemid 46190237)
20. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al: Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 27:1026-1033, 2009
21. Asgharzadeh S, Pique-Regi R, Sposto R, et al: Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 98:1193-1203, 2006 (Pubitemid 44390990)
22. Kalbfleisch J, Prentice R: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley and Sons, 1980
23. Mood AM, Garybill FA, Boes DC: Introduction to the Theory of Statistics. New York, NY, McGraw-Hill, 1974
24. Katoh M, Katoh M: Identification and characterization of FLJ10737 and CAMTA1 genes on the commonly deleted region of neuroblastoma at human chromosome 1p36.31-p36.23. Int J Oncol 23:1219-1224, 2003
25. Nakagawara A, Azar CG, Scavarda NJ, et al: Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 14:759-767, 1994
26. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al: Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328:847-854, 1993 (Pubitemid 23084339)
27. Henrich KO, Fischer M, Mertens D, et al: Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. Clin Cancer Res 12:131-138, 2006 (Pubitemid 43166186)
28. Biswas SK, Mantovani A: Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunol 11:889-896, 2010
29. Leidi M, Gotti E, Bologna L, et al: M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 182:4415-4422, 2009
30. Song L, Asgharzadeh S, Salo J, et al: Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest 119:1524-1536, 2009
31. Ara T, Song L, Shimada H, et al: Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 69:329-337, 2009
32. Tan TT, Coussens LM: Humoral immunity, inflammation and cancer. Curr Opin Immunol 19:209-216, 2007
33. Bromberg JF, Wrzeszczynska MH, Devgan G, et al: Stat3 as an oncogene. Cell 98:295-303, 1999 (Pubitemid 29380565)
34. Klein B, Zhang X, Jourdan M, et al: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73:517-526, 1989 (Pubitemid 19060538)
35. de Visser KE, Korets LV, Coussens LM: De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7:411-423, 2005 (Pubitemid 40719125)
36. Andreu P, Johansson M, Affara NI, et al: FcR-gamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17:121-134, 2010
37. Suzuki T, Bogenmann E, Shimada H, et al: Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 85:377-384, 1993 (Pubitemid 23073155)
38. Aoyama M, Asai K, Shishikura T, et al: Human neuroblastomas with unfavorable biologies express high levels of brain-derived neurotrophic factor mRNA and a variety of its variants. Cancer Lett 164:51-60, 2001 (Pubitemid 32144989)
39. Ohira M, Nakagawara A: Global genomic and RNA profiles for novel risk stratification of neuroblastoma. Cancer Sci 101:2295-2301, 2010
40. Fischer M, Spitz R, Oberthür A, et al: Risk estimation of neuroblastoma patients using molecular markers. Klin Padiatr 220:137:146, 2008
41. Attiyeh EF, London WB, Mossé YP, et al: Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353:2243-2253, 2005 (Pubitemid 41697287)
42. Oberthuer A, Hero B, Berthold F, et al: Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 28:3506-3515, 2010
43. De Preter K, Vermeulen J, Brors B, et al: Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res 16:1532-1541, 2010
44. Guo C, White PS, Hogarty MD, et al: Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas. Med Pediatr Oncol 35:544-546, 2000
45. Plantaz D, Vandesompele J, Van Roy N, et al: Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer 91:680-686, 2001 (Pubitemid 32115264)
46. Bagatell R, Rumcheva P, London WB, et al: Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol 23:8819-8827, 2005 (Pubitemid 46211528)
47. Bown N, Cotterill S, Lastowska M, et al: Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340:1954-1961, 1999 (Pubitemid 29288271)
48. Carén H, Kryh H, Nethander M, et al: High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci 107:4323-4328, 2010
49. Guo X, Chen QR, Song YK, et al: Exon array analysis reveals neuroblastoma tumors have distinct alternative splicing patterns according to stage and MYCN amplification status. BMC Med Genomics 4:35, 2011
50. Beiske K, Burchill SA, Cheung IY, et al: Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: Recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 100:1627-1637, 2009
51. 131I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 56:1041-1045, 2011
52. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
53. Beatty GL, Chiorean EG, Fishman MP, et al: CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331:1612-1616, 2011
54. Brahmer JR, Drake CG, Wollner I, et al: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167-3175, 2010